Ohio does not have a stem cell law. A full text search of the Ohio Revised Code and the Ohio Administrative Code returns no statute or rule on stem cell therapy, advertising, or disclosure. That absence is the story. This guide covers the Ohio law that does apply, how Ohio compares with Georgia and Tennessee, and the federal rules reaching every provider.
TLDR Ohio has no statute or administrative rule that specifically regulates stem cell therapy, advertising, or disclosure. What applies instead is general medical board discipline law, the state Deceptive Trade Practices Act, federal 21 CFR Part 1271, and FTC advertising standards. Georgia and Tennessee added stem cell specific notice and consent laws in 2026. Ohio did not. Banking adipose tissue does not guarantee eligibility, access, or clinical benefit from any future therapy or trial.
Important Disclaimer: Save My Fat does not provide FDA-approved treatments or cures for any disease. Banking adipose tissue today does not guarantee eligibility, access, or clinical benefit from any future therapy, clinical trial, or medical program. No adipose-derived stem cell product currently has FDA approval for any disease, and no state law changes that. All content is for educational purposes only and does not constitute medical advice. Patients must consult their own licensed healthcare professionals regarding all medical decisions.
People look for an Ohio stem cell law because they assume every state wrote one. Several did, including Georgia and Tennessee in 2026. Ohio did not. It relies on general advertising, discipline, and consumer protection law instead.
The absence matters, but not the way most people expect. A state statute here cannot approve a product, override FDA jurisdiction, or make an unapproved product legal to market. Ohio patients lose no federal protection, because 21 CFR 1271.20 applies in all 50 states. What they lose is a state mandated warning inside the advertisement.
What a Search of Ohio Law Actually Returns
Almost nothing on point. An exhaustive search of both Ohio codes, each validated with a control query, returns no state statute or rule regulating stem cell therapy, advertising, or disclosure.
The phrase “stem cell” returns exactly one section. It is ORC 3722.01, in the hospitals chapter, where “Stem cell harvesting and reinfusion” sits inside a definition of health care services. A definition, not a rule of practice.
The plural returns two more, and neither concerns clinical care. ORC 2108.62 has the Department of Health publish information on “options available to a mother regarding stem cells contained in the umbilical cord blood after delivery.” ORC 3715.601 uses the phrase in the definition of a “cultivated-protein food product,” meaning lab grown meat.
“Regenerative medicine” returns zero sections. Ohio’s Medical Practice Act, ORC Chapter 4731, contains zero occurrences of “stem cell” and zero of “regenerative.” No State Medical Board rule mentions stem cells either.
Ohio Stem Cell Advertising Rules Come From General Law
Ohio has no stem cell specific advertising rule. Three general provisions carry the weight, and one holds a carve-out that surprises people.
ORC 4731.22(B)(5) permits discipline for “Making a false, fraudulent, deceptive, or misleading statement in the solicitation of or advertising for patients.” That is the closest Ohio comes to an advertising rule here.
ORC 4165.02(A)(7), in the Deceptive Trade Practices Act, makes it a deceptive trade practice to represent “that goods or services have sponsorship, approval, characteristics, ingredients, uses, benefits, or quantities that they do not have.” Notice the word approval when a product holds none from FDA.
Then the carve-out. ORC 1345.01(A) sets the reach of the Consumer Sales Practices Act and excludes “transactions between attorneys, physicians, or dentists and their clients or patients.” Ohio’s main consumer protection statute does not reach that transaction itself. Our advertising disclosure comparison puts Ohio beside states that wrote a notice into statute.
Ohio’s Right to Try Law Does Not Mention Stem Cells
It does not. ORC 4731.97 is Ohio’s Right to Try law, enacted by SB 229 and effective March 22, 2020. It covers eligible patients with terminal conditions and an “investigational drug, product, or device” that has “successfully completed phase one of United States food and drug administration clinical trials.”
That matters because Right to Try is sometimes invoked in marketing as a general permission slip. In Ohio it is narrow, and its text never names stem cells.
How Ohio Compares With Georgia and Tennessee
Georgia and Tennessee enacted laws in 2026 requiring a verbatim advertising notice and a signed consent form. Ohio requires neither, and none of the three legalizes any therapy. The table sets out what each state asks of a physician offering a product FDA has not approved.
| Requirement | Ohio | Georgia | Tennessee |
|---|---|---|---|
| Stem cell statute | None | HB 1275 (2026 Ga. Laws Act 453) | HB 2246, Public Chapter 1016 |
| Effective date | Not applicable | July 1, 2026 | July 1, 2026, most purposes |
| Advertising notice | Not required by state | Required, verbatim text | Required, verbatim text |
| Written consent | No state requirement | Required, three disclosures | Required, contents unspecified |
| Stated penalty | Board discipline | Professional discipline | Licensing authority discipline |
Read the table as physician duties, not product status. In Georgia and Tennessee the stated penalty is professional discipline, not any bar on the product.
Georgia’s HB 1275, signed in May 2026 and effective July 1, 2026, requires set text in any form of advertisement, in a type size no smaller than the largest used in the advertisement of the services offered. Its consent form must cover the nature of the treatment, the lack of FDA approval, and the anticipated results.
Tennessee’s Public Chapter 1016, signed by Governor Bill Lee on May 19, 2026, took effect July 1, 2026 for purposes other than rulemaking. Its consent clause is thinner: a signed form is required, and the enacted law specifies no contents for it.
A state law here regulates the physician, not the product. Ohio is not among the states with an enacted stem cell specific statute, and our multi state law map tracks where the rest stand.
The Federal Rules That Apply in Ohio Regardless
Federal law is unaffected by Ohio’s silence. 21 CFR Part 1271, titled “Human Cells, Tissues, and Cellular and Tissue-Based Products,” governs human cell and tissue products in every state.
Under the four criteria at 1271.10(a), a product falls solely under section 361 only if it is minimally manipulated, for homologous use only, not combined with another article beyond narrow exceptions, and either without systemic effect or limited to autologous, close relative, or reproductive use. The second criterion names “labeling, advertising, or other indications of the manufacturer’s objective intent.” Advertising sits inside the regulation.
Anything failing those criteria and not otherwise excepted “will be regulated as a drug, device, and/or biological product” under section 1271.20, meaning an investigational new drug application to study it and a biologics license application to market it.
FDA treats adipose as structural tissue in its July 2020 guidance, which states that isolating stromal vascular fraction is “generally considered more than minimally manipulated” because processing eliminates the adipocytes and surrounding structural components that provide cushioning and support.
One more point matters for Ohio advertising. Tissue establishment registration is self submitted. FDA’s patient information page states that “the fact that a firm has registered with FDA and listed its product does not mean the product is legally marketed.” Registration is not approval or endorsement.
What Ohio Patients Should Ask a Provider First
Ask what Georgia and Tennessee law would have placed inside the advertisement. In Ohio nobody has to volunteer it.
Start by asking whether the product is FDA approved for your condition. No adipose derived product is FDA approved for any disease. Then ask whether you are being charged outside a clinical trial. The FDA page quoted earlier says such patients “are likely being deceived and offered a product illegally.”
Next, ask what evidence supports the claim. FTC’s health products guidance calls randomized, controlled human clinical trials “the most reliable form of evidence.” Finally, ask whether testimonials are being offered as proof. Under 16 CFR 255.2, “Consumer endorsements themselves are not competent and reliable scientific evidence.”
FTC also treats vague qualifiers such as “may” or “promising” as inadequate to communicate scientific limitations. A provider who cannot answer the first two questions plainly has told you something.
Where Adipose Tissue Banking Fits, and Where It Does Not
Banking is a preservation decision, not a medical one, and Ohio’s silence changes nothing about it. Save My Fat is a connector. It links patients and providers with a U.S. tissue bank. It does not collect, process, store, or treat tissue, and it is not a clinic, not a bank, and not a medical practice.
Adipose tissue and anything derived from it, including stromal vascular fraction and culture expanded adipose derived stromal cells, is investigational and not FDA approved for any disease. The science is early stage. FDA’s consumer alert states that no regenerative medicine products are approved for orthopedic conditions, neurological disorders, cardiovascular or pulmonary disease, autism, blindness, or chronic pain.
So banking should be weighed as what it is. It preserves a person’s own tissue and nothing more. It guarantees no eligibility, access, or clinical benefit from any future therapy, trial, or program, and any future use would depend on FDA regulatory status, physician guidance, and the pathways available then. Anyone considering it should raise it with their own licensed healthcare professional.
Frequently Asked Questions
Does Ohio have a stem cell law?
No. A validated search of the Revised Code and the Administrative Code returns no statute or rule on stem cell therapy, advertising, or disclosure. The few mentions sit in a hospital services definition, a cord blood information duty, and a food product definition.
If Ohio has no law, is an unapproved therapy allowed there?
State silence is not permission. Ohio’s legislature regulates licensure and discipline, not products. Product status is federal, and 21 CFR 1271.20 applies in Ohio as everywhere else. A product failing the 1271.10(a) criteria needs federal authorization before it can be studied or marketed.
Does an Ohio advertisement have to say a therapy is not FDA approved?
Not under a stem cell specific state law, because Ohio has none. Georgia and Tennessee require a verbatim notice. Ohio providers still answer to ORC 4731.22(B)(5), the Deceptive Trade Practices Act, and federal FTC standards, which reach deceptive claims without prescribing wording.
Does banking adipose tissue in Ohio create access to a future therapy?
No. Banking preserves a person’s own tissue. It does not guarantee eligibility, access, or clinical benefit from any future therapy, trial, or program, and it connects no one to a treatment pathway.
Key Takeaways
Ohio has no stem cell statute and no stem cell rule. General law governs instead: board discipline under ORC 4731.22(B)(5), the Deceptive Trade Practices Act at ORC 4165.02(A)(7), a Consumer Sales Practices Act that excludes the physician and patient transaction, and a Right to Try statute that never names stem cells. Georgia and Tennessee added notice and consent duties in 2026 and Ohio did not, so no state mandated warning appears in an Ohio advertisement. Federal law is unchanged either way, because 21 CFR Part 1271 applies in every state. Banking adipose tissue preserves tissue and guarantees no clinical benefit.
Save My Fat operates as a tissue preservation service, not a medical practice or treatment provider. Stem cell and regenerative medicine regulations vary by state, including specific informed-consent and disclosure requirements in Florida, Utah, and Nevada governing tissue and stem cell services. Banking adipose tissue does not connect patients to any treatment pathway, and any future use depends on FDA regulatory status, physician guidance, and the availability of approved or investigational pathways at that time.
Readers weighing adipose tissue banking for potential future use can review current pricing or open a conversation through the contact page.
Save My Fat partners with L2 Bio for laboratory processing and storage.
This article is for educational purposes only and does not constitute medical or legal advice. Legal and medical review including neurology and neurosurgery input is required before publication. Please consult your neurologist or neurosurgeon before making any decisions about adipose tissue banking or research participation.
About the author: Oscar Tellez is the founder and CEO of Save My Fat. He holds a Bachelor of Science in Exercise Science and Health Promotion from Florida Atlantic University. He has spent more than a decade in the regenerative medicine industry across product distribution, laboratory and vendor relationships, and provider training. He is not a licensed clinician, and this article is educational, not medical advice.
Related guide: state stem cell laws.
